Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PragMet
NCT05515978Phase 1Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2022
- Primary completion
- Oct 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in prostate cancer (PCa), glucose intolerance and Overweight (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Successful accrual of 100 patients at 4 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
prostate cancer (PCa)glucose intoleranceOverweight
Beyond the preview
Go deeper on NCT05515978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515978.